News Sentiment

TMDX sentiment intelligence

TransMedics Group Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 71.23 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

75/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+3.4% over one week, -2.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

TransMedics Group (TMDX) Stock Still Looks Below Fair Value After A 154% Run

Market Reaction

Balanced read

62/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 75/100 classification
One-week reaction 3.4% Price confirming higher
Trend fit Trend inactive -2.3% over four weeks
Fair value -29.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 38
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 10
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
TradingView 6
Stock Titan 5
simplywall.st 4
MarketBeat 4
Quartr 4
PR Newswire 3
Seeking Alpha 3

Event Lens

What the news is about

Classified themes
Earnings 26
Market update 24
Analyst action 6
Regulatory and legal 2
Balance sheet 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
Capital.com Direct company coverage

TransMedics Group Inc (TMDX) Stock Price Quote Today & Current Price Chart | Capital.com EU

This page provides current stock information for TransMedics Group Inc (TMDX), including its stock price quote, key statistics, and a company overview. It highlights TMDX as a medical technology company focused on organ transplant therapy with its OCS products. The article also t

Tone
Positive 65/100
Event
Market update
Published
16 Jul 2026 14:40
Source
Capital.com
MarketBeat Direct company coverage

Regency Capital Management Inc. DE Purchases Shares of 21,846 TransMedics Group, Inc. $TMDX

Regency Capital Management Inc. DE has acquired 21,846 shares of TransMedics Group, Inc. (NASDAQ:TMDX) valued at approximately $2.17 million during the first quarter. This makes Regency Capital Management Inc. DE the owner of about 0.06% of the company's stock. Insider transactio

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 11:12
Source
MarketBeat
Quartr Direct company coverage

TransMedics Group (TMDX) 44th Annual J.P. Morgan Healthcare Conference Summary

TransMedics Group (TMDX) provided a summary of their 44th Annual J.P. Morgan Healthcare Conference, outlining significant strategic, technological, clinical, and operational advancements. Key points include plans for a new facility in Somerville, the development of their OCS mult

Tone
Positive 92/100
Event
Market update
Published
16 Jul 2026 01:39
Source
Quartr
Stock Titan Direct company coverage

TransMedics Group (TMDX) CEO receives major RSU and stock option grants

TransMedics Group's President & CEO, Waleed H. Hassanein, received significant equity awards on July 10, 2026, including 49,669 restricted stock units and stock options for 112,984 shares at an exercise price of $71.23. These options will vest monthly until April 2030, contingent

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 12:12
Source
Stock Titan
Stock Titan Direct company coverage

TransMedics Group (TMDX) awards RSUs and stock options to officer

TransMedics Group (TMDX) has granted equity compensation to officer Nicholas Corcoran, including 11,727 restricted stock units (RSUs) and a stock option for 17,784 shares. The stock option has an exercise price of $71.23 per share and vests monthly, with full vesting expected by

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 02:43
Source
Stock Titan
Stock Titan Direct company coverage

TransMedics Group (NASDAQ: TMDX) grants CFO 17,246 RSUs and 26,153 stock options

TransMedics Group's CFO, Gerardo Hernandez, was granted 17,246 Restricted Stock Units (RSUs) and 26,153 stock options on July 10, 2026. The stock options have an exercise price of $71.23 per share and will vest monthly from April 10, 2026, through April 10, 2030. Following these

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 02:43
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 TransMedics Group Inc For: 14 July By Investing.com

This article from Investing.com reports on a Form 4 filing for TransMedics Group Inc (TMDX) on July 14th. Form 4s disclose transactions made by company insiders. The brief news piece provides no further details on the specific transactions but notes the company's stock performanc

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 01:43
Source
Investing.com Nigeria
AlphaStreet Direct company coverage

TransMedics Group Jumps 6.7% Amid Sector-Wide Rally

TransMedics Group's stock surged 6.7% to $75.97, reflecting a broad rally across the medical device sector rather than company-specific news. The organ transplant technology company's market capitalization reached $2.7 billion with significant trading volume, outperforming peers

Tone
Positive 74/100
Event
Market update
Published
14 Jul 2026 12:12
Source
AlphaStreet
MarketBeat Direct company coverage

Candriam S.C.A. Buys 49,580 Shares of TransMedics Group, Inc. $TMDX

Candriam S.C.A. increased its holdings in TransMedics Group, Inc. by 45.4% in the first quarter, purchasing an additional 49,580 shares to bring its total to 158,766 shares valued at $15.8 million. Other institutional investors also adjusted their positions, while Director Thomas

Tone
Neutral 50/100
Event
Earnings
Published
12 Jul 2026 15:10
Source
MarketBeat
Quartr Direct company coverage

TransMedics Group (TMDX) Proxy filing Summary

TransMedics Group (TMDX) has filed a proxy statement proposing an amendment to its 2019 Stock Incentive Plan. The amendment seeks to add 2,750,000 shares and enhance governance, supporting the company's significant growth from $30 million in revenue in 2021 to $605.5 million in 2

Tone
Positive 66/100
Event
Earnings
Published
11 Jul 2026 08:42
Source
Quartr
Quartr Direct company coverage

TransMedics Group (TMDX) Q3 2025 earnings summary

TransMedics Group (TMDX) reported strong Q3 2025 results, with revenue reaching $143.8 million, a 32.2% year-over-year increase, and net income soaring to $24.3 million. The growth was driven by increased OCS utilization, particularly in liver and heart transplants through the Na

Tone
Positive 82/100
Event
Earnings
Published
08 Jul 2026 22:42
Source
Quartr
Quartr Direct company coverage

TransMedics Group (TMDX) Q1 2026 earnings summary

TransMedics Group (TMDX) announced Q1 2026 revenue of $173.9 million, a 21% year-over-year increase, driven by OCS Liver sales, NOP usage, and logistics services. Despite growth, gross margin declined to 58%, and operating expenses rose due to investments. The company reiterated

Tone
Positive 70/100
Event
Earnings
Published
08 Jul 2026 15:11
Source
Quartr
Simply Wall Street Direct company coverage

TransMedics Group (TMDX) Expands Into Europe, Is The Stock Still Undervalued?

TransMedics Group (TMDX) has expanded into Europe by investing in Germany-based PAD Aviation, aiming to replicate its Organ Care System Network Operating Platform and build a pan-European organ transplant logistics network. Despite recent stock declines, at US$71.12, the company

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 11:09
Source
Simply Wall Street
Insider Monkey Direct company coverage

10 Best Innovative Healthcare Stocks to Buy Now

TransMedics Group, Inc. (NASDAQ:TMDX) is highlighted as an innovative healthcare stock, with 40 hedge funds holding stakes. The company recently announced a strategic investment in PAD Aviation to expand its Organ Care System (OCS) program into Europe, aiming to enhance organ tra

Tone
Positive 70/100
Event
Market update
Published
07 Jul 2026 21:09
Source
Insider Monkey
PR Newswire Direct company coverage

TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH

TransMedics Group, Inc. has announced the completion of its strategic investment in PAD Aviation service GmbH, a German-based private aviation operator. This investment is crucial for TransMedics to establish a dedicated pan-European organ transplantation air logistics network, a

Tone
Positive 71/100
Event
Market update
Published
06 Jul 2026 10:39
Source
PR Newswire
Finviz Direct company coverage

TMDX - Transmedics Group Inc Latest SEC Filings

This article provides the latest SEC filings information for Transmedics Group Inc (TMDX), along with comprehensive financial data. It includes key figures such as market capitalization, income, sales, various financial ratios, stock performance metrics, and analyst recommendatio

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jul 2026 21:10
Source
Finviz
The Globe and Mail Direct company coverage

3 Growth Stocks to Buy on the Dip

This article suggests three growth stocks—SoFi Technologies, Robinhood Markets, and TransMedics Group—that investors should consider buying after recent dips in their stock prices. Despite facing challenges such as short-seller reports or disappointing quarterly results, all thre

Tone
Positive 66/100
Event
Earnings
Published
02 Jul 2026 23:09
Source
The Globe and Mail
TradingView Direct company coverage

TMDX Stock Rallies As Analyst Sees 77% Upside — Here’s Why

TransMedics Group Inc (TMDX) stock rallied after TD Cowen maintained a 'Buy' rating and a $120 price target, citing strong growth in U.S. transplant activity, particularly in heart, liver, and lung procedures, as a key driver for the company's Organ Care System (OCS) technology a

Tone
Positive 82/100
Event
Analyst action
Published
02 Jul 2026 08:09
Source
TradingView
TradingView Direct company coverage

Reasons to Retain TransMedics Stock in Your Portfolio for Now

TransMedics Group, Inc. (TMDX) is positioned for growth due to its innovative Organ Care System (OCS) technology and solid first-quarter 2026 results. Despite a year-to-date stock decline and gross margin pressures, the company's robust pipeline, including next-generation OCS sys

Tone
Positive 59/100
Event
Earnings
Published
30 Jun 2026 17:09
Source
TradingView
MarketBeat Direct company coverage

TransMedics Group (NASDAQ:TMDX) Earns Buy Rating from Canaccord Genuity Group

Canaccord Genuity Group has reiterated a "buy" rating for TransMedics Group (NASDAQ:TMDX) with a $124.00 price target, suggesting a potential upside of 88.28%. Despite this, the stock was down 2.1% to $65.86, trading well below its 52-week high. The company's recent earnings show

Tone
Neutral 50/100
Event
Analyst action
Published
30 Jun 2026 16:09
Source
MarketBeat
Stock Traders Daily Direct company coverage

Liquidity Mapping Around (TMDX) Price Events

This article provides an AI-generated liquidity mapping and trading strategies for Transmedics Group Inc. (NASDAQ: TMDX). Key findings indicate near-term weak sentiment, with no clear price positioning signal and elevated downside risk. The analysis offers specific institutional

Tone
Negative 39/100
Event
Balance sheet
Published
29 Jun 2026 07:38
Source
Stock Traders Daily
TradingView Direct company coverage

Price to sales forward of TransMedics Group, Inc. – NASDAQ:TMDX

The article provides a snapshot of the forward price-to-sales ratio for TransMedics Group, Inc. (NASDAQ: TMDX). While the specific value is not detailed in the provided text, it indicates that the information regards a financial metric for the company. The content appears to be a

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 10:09
Source
TradingView
The National Law Review Direct company coverage

TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz

Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential corporate wrongdoing by TransMedics Group, Inc. (TMDX). The firm is encouraging investors who purchased TransMedics securities prior to February 3, 2022, and still hold them, to contact them to learn

Tone
Negative 40/100
Event
Regulatory and legal
Published
27 Jun 2026 18:40
Source
The National Law Review